Dr Filippo Pietrantonio speaks to ecancer about the CodeBreak 300 phase III study.

The study reported results for sotorasib, a KRASG12C-inhibitor, and panitumumab, an anti-EGFR antibody, compared to standard of care in patients with chemorefractory KRAS G12C-mutated mCRC.

In this study, the primary endpoint was met and both doses of sotorasib and panitumumab showed superior progression-free survival (PFS) compared to standard of care.

This combination demonstrated clinically meaningful benefits across PFS and key secondary endpoints and was tolerable with lower rates of Grade ≥3 treatment-related adverse events.